Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sunitinib Malate Capsules in Healthy Volunteers
NCT05800106Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sunitinib in gastrointestinal stromal tumor (GIST), renal cell carcinoma (RCC) and Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum plasma concentration at 168 hours, Time to maximum concentration at 168 hours and 6 more. Started Dec 2018; status: completed.
02
Drugs
sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)renal cell carcinoma (RCC)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05800106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800106.